Tuberculosis in the Czech Republic in the Year 2004
Authors:
J. Homolka; F. Krejbich; V. Mazánková 1
Authors‘ workplace:
I. klinika tuberkulózy a respiračních nemocí 1. LF UK a VFN, Praha
; Ústav zdravotnických informací a statistiky České republiky, Praha
1
Published in:
Čas. Lék. čes. 2005; 144: 587-591
Category:
Topic
Overview
The number of notified TB cases in the Czech Republic continued to decrease in the year 2004. 1057 new TB cases and relapses of TB were reported in the year 2004 (10.3/100 000). 861 were pulmonary TB (8.4/100 000) and from those 584 were unequivocal pulmonary TB cases (5,7/100 000). The decreasing trend in TB incidence reported since 1998 has continued. Treatment success was present in 76.7 % of cases; failures and interrupted treatment were observed in only 2.0 %. Results of the treatment were affected by great numbers of deaths for other causes then TB, because they were observed in the oldest part of population. The resistance for AT drugs was confirmed in less then 6% of cases and MDR-cases were under 2%. The low level of resistance and good treatment outcomes are very important for further decline of new TB cases. The next target of TB control should be the active case finding in high-risk groups and monitoring latent TB infection.
Key words:
tuberculosis, epidemiology, treatment, resistance, risk groups.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistArticle was published in
Journal of Czech Physicians
![Issue 9](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/92981e385e8c481fc28155f3a915af91.jpeg)
Most read in this issue
- Latex Allergy – Report on Two Cases
- Differential Diagnosis of Peripheral Neuropathy
- Treatment of the Unresectable Non Small Cell Lung Carcinoma
- Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma The First Experience in the Czech Republic